Assessing the risk of a clinically significant infection from a Microneedle Array Patch (MAP) product.

MLA

Dul, Maria, et al. “Assessing the Risk of a Clinically Significant Infection from a Microneedle Array Patch (MAP) Product.” Journal of Controlled Release : Official Journal of the Controlled Release Society, vol. 361, Sept. 2023, pp. 236–45. EBSCOhost, https://doi.org/10.1016/j.jconrel.2023.07.001.

APA

Dul, M., Alali, M., Ameri, M., Burke, M. D., Craig, C. M., Creelman, B. P., Dick, L., Donnelly, R. F., Eakins, M. N., Frivold, C., Forster, A. H., Gilbert, P.-A., Henke, S., Henry, S., Hunt, D., Lewis, H., Maibach, H. I., Mistilis, J. J., Park, J.-H., … Coulman, S. A. (2023). Assessing the risk of a clinically significant infection from a Microneedle Array Patch (MAP) product. Journal of Controlled Release : Official Journal of the Controlled Release Society, 361, 236–245. https://doi.org/10.1016/j.jconrel.2023.07.001

Chicago

Dul, Maria, Mohammed Alali, Mahmoud Ameri, Matthew Douglas Burke, Christine M Craig, Benjamin Paul Creelman, Lisa Dick, et al. 2023. “Assessing the Risk of a Clinically Significant Infection from a Microneedle Array Patch (MAP) Product.” Journal of Controlled Release : Official Journal of the Controlled Release Society 361 (September): 236–45. doi:10.1016/j.jconrel.2023.07.001.